platoseedplatoseed
Potent, durable, and redosable non-viral genetic medicines
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.
Engage Bio is developing a non-viral DNA delivery platform called Tethosome to achieve potent, durable, and re-dosable genetic medicines. Their approach uses LNP technology to deliver therapeutic DNA and an mRNA encoding a Tethosome protein that localizes DNA to the nucleus while avoiding immune detection.
The platform delivers therapeutic DNA and Tethosome mRNA via LNPs. The Tethosome protein tethers DNA to the nucleus, enabling expression of DNA with over 100x potency compared to traditional non-viral DNA, while being non-immunogenic and invisible to immune sensors. The system supports re-dosability and tunable expression, with low manufacturing complexity and proven LNP technology to enable scalable production.
Who it’s for: Biotech/health startups and pharmaceutical companies focused on gene therapy and DNA-based medicines seeking non-viral delivery solutions.
Hiring/Careers mentions; platform and leadership details; ongoing recruitment and openings indicate early-stage growth
Creating a New Class of Drugs to Address Incurable Autoimmune Diseases
Creating new protein-based drugs at scale
